Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*.

scientific article published in December 2005

Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/BRAIN/AWH666
P698PubMed publication ID16251215
P5875ResearchGate publication ID7515872

P50authorAlexander ZimprichQ30500607
Peter LichtnerQ30500645
Daniela BergQ30500724
Zbigniew K WszolekQ64754704
Thomas GasserQ64856147
Katherine J SchweitzerQ117251262
P2093author name stringClaudia Schulte
Thomas Nägele
Petra Belcredi
Petra Leitner
Theresa Brüssel
Sylvia Maass
P433issuePt 12
P407language of work or nameEnglishQ1860
P921main subjectParkinson's diseaseQ11085
P304page(s)3000-3011
P577publication date2005-12-01
P1433published inBrainQ897386
P1476titleType and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*.
P478volume128

Reverse relations

cites work (P2860)
Q61805965A Comprehensive Analysis of Population Differences in Variant Distribution in Parkinson's Disease
Q47157967A Critical Assessment of Exosomes in the Pathogenesis and Stratification of Parkinson's Disease.
Q43501182A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2.
Q45817386Ancient origin of the Parkinson disease gene LRRK2.
Q92131837Binding of the Human 14-3-3 Isoforms to Distinct Sites in the Leucine-Rich Repeat Kinase 2
Q37943645Biomarkers of Parkinson's disease and Dementia with Lewy bodies
Q40346416Characterization of the Roco protein family in Dictyostelium discoideum
Q37081406Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations
Q35982596Cognitive Impairments in LRRK2-Related Parkinson's Disease: A Study in Chinese Individuals
Q54571312Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease.
Q36748778Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations
Q26827527Current Understanding Of LRRK2 In Parkinson’s Disease: Biochemical And Structural Features And Inhibitor Design
Q36854642Deciphering the role of heterozygous mutations in genes associated with parkinsonism
Q33611632Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors
Q35819806Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis
Q48296649Effective long-term subthalamic stimulation in PARK8 positive Parkinson's disease
Q38746811Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinson's Disease
Q28551962Functional and Morphological Correlates in the Drosophila LRRK2 loss-of-function Model of Parkinson's Disease: Drug Effects of Withania somnifera (Dunal) Administration
Q38044428Genetic analysis of Parkinson's disease-linked leucine-rich repeat kinase 2
Q50265751Genetic and clinical analysis in a Chinese parkinsonism-predominant spinocerebellar ataxia type 2 family
Q38115298Genetic basis of Parkinson's disease: inheritance, penetrance, and expression
Q22252904Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update
Q36499640Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?
Q34470633Genetics of Parkinson's disease: LRRK2 on the rise
Q33689486Hyperechogenicity of the substantia nigra: pitfalls in assessment and specificity for Parkinson’s disease
Q39849125Identifying PD-causing genes and genetic susceptibility factors: current approaches and future prospects
Q92702096Improvements of Motor Performances in the Drosophila LRRK2 Loss-of-Function Model of Parkinson's Disease: Effects of Dialyzed Leucocyte Extracts from Human Serum
Q64785219Induced pluripotent stem cell-based modeling of mutant LRRK2-associated Parkinson's disease
Q38044434Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models
Q37542688Integrating Gene Correction in the Reprogramming and Transdifferentiation Processes: A One-Step Strategy to Overcome Stem Cell-Based Gene Therapy Limitations
Q22252940Interface between tauopathies and synucleinopathies: A tale of two proteins
Q42737973Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities
Q35498549Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant
Q33340326LRRK2 Gly2385Arg mutation and clinical features in a Chinese population with early-onset Parkinson's disease compared to late-onset patients
Q24292798LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool
Q41785779LRRK2 dephosphorylation increases its ubiquitination
Q47718405LRRK2 gene variation and its contribution to Parkinson disease
Q33382857LRRK2 in Parkinson's disease - drawing the curtain of penetrance: a commentary
Q24298891LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex
Q36794416LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease
Q33682480LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease
Q28602836LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias
Q38738200Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
Q48308813Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease
Q33812599Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease
Q24293453Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain
Q35811884Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway
Q33649391Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain
Q33282375Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection.
Q47406006Mechanistic contributions of FBXO7 to Parkinson disease.
Q34986076Models for LRRK2-Linked Parkinsonism
Q58114516Models of Sporadic Parkinson's Disease
Q28266683Molecular genetic findings in LRRK2 American, Canadian and German families
Q37561699Molecular pathogenesis of Parkinson disease: insights from genetic studies
Q36193915Olfaction in Parkinson's disease and related disorders
Q47797902Olfactory dysfunction in sporadic Parkinson's Disease and LRRK2 carriers
Q24338647Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity
Q89786852Parkinson's disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging
Q34140428Parkinson's disease: Exit toxins, enter genetics
Q22242870Parkinson's disease: from monogenic forms to genetic susceptibility factors
Q42324120Parkinson's disease: leucine-rich repeat kinase 2 and autophagy, intimate enemies.
Q94371699Parkinson’s Disease
Q40784600Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2.
Q38182492Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2).
Q36226461Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort.
Q58486541Prevention of progression in Parkinson's disease
Q30483115R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice.
Q35692655Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers
Q53459145Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles.
Q33785923Substantia nigra hyperechogenicity is a risk marker of Parkinson’s disease: yes
Q37778568TCS in Monogenic Forms of Parkinson’s Disease
Q42509261The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway
Q24293505The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity
Q36154267The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity
Q36982616The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules
Q28259566The pleomorphic pathology of inherited Parkinson's disease: lessons from LRRK2
Q42376536The role of gene variants in the pathogenesis of neurodegenerative disorders as revealed by next generation sequencing studies: a review
Q26746174Theoretical Approaches to Lentiviral Mediated Neurotrophin Delivery in Potential Treatments of Parkinson's Disease
Q90359253Tied up: Does altering phosphoinositide-mediated membrane trafficking influence neurodegenerative disease phenotypes?
Q33614776Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson's disease
Q28085293Usefulness of Genetic Testing in PD and PD Trials: A Balanced Review
Q38092552Using viral-mediated gene delivery to model Parkinson's disease: Do nonhuman primate investigations expand our understanding?
Q92017939What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations?
Q37313530Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.

Search more.